hapabapa Agilent Technologies (NYSE:A) offers instruments, consumables, software and services to life sciences, diagnostics and applied chemical markets. Agilent has made significant efforts in transforming its business towards growth areas including biopharma, polyfluoroalkyl substances (PFAS) testing and advanced materials for semiconductor. I am initiating a ‘Buy’ rating with a one-year target price of $160 per share. Growing Biopharma, PFAS & Advanced Materials Agilent offers workflow solutions for ...

Agilent Technologies (A) has delivered third-quarter fiscal 2024 earnings of $1.32 per share, which beat the Zacks Consensus Estimate by 5.6%. However, the bottom line decreased 8% from the year-ago quarter. Revenues of $1.58 billion beat the Zacks Consensus Estimate of $1.56 billion. The top line declined 5.6% on a reported basis and 4.4% on a core basis from the year-ago quarter. The decline was attributed to broad-based weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and G ...

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%. Adjusted EPS of $1.32 surpassed the street view of $1.26.Agilent said it sees fourth-quarter revenue of $1.641 billion – $1.691 b ...

Agilent Technologies (NYSE:A) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32. This was above the analyst estimate for EPS of $1.26. The company reported revenue of $1.58 billion. This was 1.15% better than the analyst estimate for revenue of $1.56 billion. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings pe ...

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $1.578 billion, a decline of 4.4%, but an improvement of 300 basis points from Q2 [6][18] - Operating margin improved to 27.4%, reflecting the effectiveness of cost-saving measures [6][22] - Earnings per share (EPS) was $1.32, exceeding guidance by $0.04, but down 7.7% year-over-year [6][22] Business Line Data and Key Metrics Changes - Life Sciences and Applied Markets Group (LSAG) reported revenue of $782 million, down 7%, with consumables growing mid-single digits [10][11] - Agilent CrossLab Group (ACG) delivered revenue of $411 million, up mid-single digits, with a record operating margin of 34% [12] - Diagnostics and Genomics Group (DGG) posted revenue of $385 million, representing an 8% decline, with pathology growing mid-single digits [13] Market Data and Key Metrics Changes - The largest market, pharma, declined high-single-digits, with biopharma under pressure but small molecule performing relatively better [9][19] - Europe exceeded expectations, driven by small-molecule pharma and environmental markets, while China saw an 11% decline [10][21] - Environmental & Forensics grew 4%, supported by strong performance in PFAS testing [20] Company Strategy and Development Direction - The company is focused on biopharma, PFAS, and Advanced Materials as key growth vectors [8] - Agilent is investing in its digital ecosystem to enhance customer experience and accelerate value creation [7] - Two acquisitions were announced to strengthen capabilities in biopharma and digital solutions, with a focus on enhancing recurring revenue [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady market improvement and raised guidance for revenue and EPS for the full year [6][24] - The company is adapting its strategy to market trends while maintaining a focus on customer relationships and innovation [8][27] - Management noted that while capital equipment budgets remain constrained, lab activity is improving, particularly in services and consumables [10][21] Other Important Information - The company announced the acquisition of BIOVECTRA, enhancing capabilities in oligonucleotides and CRISPR therapeutics [15] - The acquisition of Sigsense aims to optimize lab operations through AI technology [16] - Agilent's ESG report highlighted a commitment to sustainability, with 40% of instrument revenue coming from certified products [17] Q&A Session Summary Question: Insights on LSAG performance and instrument demand - Management noted strong growth in consumables and services, with stable lab activity, but instrument demand remains challenged [30][31] Question: Trends in Academic & Government market - A decline of 11% was noted, with stable funding in most regions, but a reallocation towards defense in Europe [33][34] Question: NASD performance and future expectations - NASD is expected to see a sequential step-up in Q4, with strong bookings activity indicating a return to growth [36][41] Question: Outlook for China and capital spending - Management is optimistic about mid-term recovery in China, with increased lab activity and services despite current demand constraints [45][47] Question: Margin expectations for 2025 - Continued efficiency improvements are expected, with a commitment to achieving $100 million in cost savings by the end of 2024 [49][50] Question: Instrumentation trends and recovery - Management indicated cautious optimism, with a stable order book and positive customer sentiment, although recovery is expected to be slow [74][75]

For the quarter ended July 2024, Agilent Technologies (A) reported revenue of $1.58 billion, down 5.6% over the same period last year. EPS came in at $1.32, compared to $1.43 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of +0.99%. The company delivered an EPS surprise of +5.60%, with the consensus EPS estimate being $1.25.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.60%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.19 per share when it actually produced earnings of $1.22, delivering a surprise of 2.52%. Over the last four ...

Revenue Performance - Revenue for Q3 2024 was $1.58 billion, a decline of 5.6% reported and 4.4% core year-over-year[2] - Full-year revenue outlook revised to $6.450 billion to $6.500 billion, reflecting a decline of 5.6% to 4.9% reported[8] - Fourth-quarter revenue outlook expected between $1.641 billion and $1.691 billion, indicating a decline of 2.8% to an increase of 0.2% reported[8] - Overall GAAP revenue for Agilent decreased by 6% year-over-year, from $1,672 million in Q3'23 to $1,578 million in Q3'24[39] - Agilent's core non-GAAP revenue decreased by 5% year-over-year, from $1,670 million in Q3'23 to $1,578 million in Q3'24[40] Segment Performance - Life Sciences and Applied Markets Group (LSAG) reported Q3 revenue of $782 million, down 8% reported year-over-year[5] - Diagnostics and Genomics Group (DGG) reported Q3 revenue of $385 million, a decrease of 9% reported year-over-year[7] - Agilent CrossLab Group (ACG) reported Q3 revenue of $411 million, an increase of 4% reported year-over-year[6] - Life Sciences and Applied Markets Group revenue decreased by 8% year-over-year, from $854 million in Q3'23 to $782 million in Q3'24[34] - Diagnostics and Genomics Group revenue declined by 9% year-over-year, from $422 million in Q3'23 to $385 million in Q3'24[35] - Agilent CrossLab Group revenue increased by 4% year-over-year, from $396 million in Q3'23 to $411 million in Q3'24[36] - Non-GAAP revenue for Life Sciences and Applied Markets Group showed a constant currency decline of 8% year-over-year[40] - Non-GAAP revenue for Diagnostics and Genomics Group also reflected an 8% decline year-over-year[40] Income and Earnings - GAAP net income was $282 million, with earnings per share (EPS) of $0.97, up 155% from Q3 2023[2] - Non-GAAP net income was $385 million, with EPS of $1.32, down 8% from the same quarter last year[2] - Non-GAAP earnings guidance for fiscal year 2024 revised to a range of $5.21 to $5.25 per share[8] - Net income for the period reached $938 million, a 22.6% increase compared to $765 million for the same period in 2023[23] - The company incurred restructuring and related costs of $67 million during the period, contributing to a diluted EPS impact of $0.23[26] Cash Flow and Assets - Cash flows from operating activities amounted to $1,270 million, slightly up from $1,256 million year-over-year[23] - The company reported a cash balance of $1,782 million at the end of the period, up from $1,332 million a year earlier, marking a 33.6% increase[23] - Total assets increased to $10,996 million as of July 31, 2024, up from $10,763 million on October 31, 2023, representing a growth of 2.16%[22] Liabilities and Equity - Total current liabilities surged to $2,389 million, a significant increase from $1,603 million in the previous period, reflecting a rise of 48.9%[22] - Long-term debt decreased to $2,137 million from $2,735 million, indicating a reduction of 22%[22] - Employee compensation and benefits liabilities decreased to $309 million from $371 million, a decline of 16.7%[22] - The total stockholders' equity increased to $5,903 million from $5,845 million, reflecting a growth of 0.99%[22] Management Insights - The company continues to invest in promising growth opportunities and strategic transformation initiatives to drive margin expansion[1] - Agilent's management emphasizes the importance of non-GAAP measures for evaluating core business performance, which may differ from GAAP results[30] Margins - The gross margin for Life Sciences and Applied Markets Group was 60.2% in Q3'24, slightly up from 60.1% in Q3'23[34] - The operating margin for Diagnostics and Genomics Group decreased to 18.3% in Q3'24 from 22.7% in Q3'23[35]

Agilent Technologies (A) introduced an advanced gas chromatography/mass spectrometry (GC/MS) column technology product namely J&W 5Q GC/MS Columns, in order to expand its Life Sciences and Applied Markets (LSAG) segment.The new GC/MS columns are designed to enhance GC/MS workflows and boost system performance in challenging conditions. With the help of J&W 5Q GC/MS Columns, Agilent strives to meet the demands of modern analytical laboratories. The new columns reduce the frequency of column changes and impro ...

Agilent Technologies (A) is set to report its third-quarter fiscal 2024 results on Aug 21.For the fiscal third quarter, the company expects revenues of $1.535-$1.575 billion, suggesting a decline of 8.2-5.8% on a reported basis and 6.9-4.5% on a core basis from the year-ago quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.56 billion, implying a decline of 6.6% from the year-ago quarter’s reported figure.Agilent’s non-GAAP earnings per share are expected to be $1.25-$1.28. The Zac ...